Boris Peaker
Stock Analyst at TD Cowen
(2.05)
# 2,938
Out of 4,944 analysts
19
Total ratings
36.36%
Success rate
9.73%
Average return
Main Sectors:
Stocks Rated by Boris Peaker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Downgrades: Hold | n/a | $1.66 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $53.79 | +85.91% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $3.09 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $24.96 | +100.36% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $31.55 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $7.72 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $8.79 | +229.92% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $1.78 | - | 2 | Jul 11, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $25.72 | - | 1 | Mar 15, 2022 | |
| NCNA NuCana | Downgrades: Market Perform | n/a | $4.55 | - | 1 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $52.37 | - | 1 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $646.60 | - | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $95 → $102 | $82.71 | +23.32% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.77 | - | 1 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.77 | - | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.81 | - | 1 | Jul 24, 2017 |
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.66
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $53.79
Upside: +85.91%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.09
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $24.96
Upside: +100.36%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $31.55
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $7.72
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $8.79
Upside: +229.92%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.78
Upside: -
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $25.72
Upside: -
NuCana
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.55
Upside: -
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $52.37
Upside: -
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $646.60
Upside: -
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $82.71
Upside: +23.32%
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.77
Upside: -
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -
Jul 24, 2017
Initiates: Outperform
Price Target: n/a
Current: $6.81
Upside: -